+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hepatitis Therapeutics Market by Disease Type, Drug Class, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 220 Pages
  • November 2021
  • Region: Global
  • Allied Market Research
  • ID: 5533807
Description Jump to:
The global hepatitis therapeutics market was valued at $14,480 Million in 2020 and is projected to reach $19,716 Million by 2030 registering a CAGR of 3.1% from 2021 to 2030.



Hepatitis is inflammation of liver caused due to viral infection. Hepatitis is caused due to various viruses known as virus A, virus B, virus C, virus D, virus E and virus G. The infection leads to inflammation of liver tissues, which can lead to liver cirrhosis and cancer. The infection reduces liver function and damage to other body functions. Hepatitis can be acute and chronic both. Among all the types, hepatitis B and C are the most life-threatening and difficult to treat.

The growth of the hepatitis therapeutics market is driven by rise in prevalence of various hepatitis, increase in R&D, clinical trials of hepatitis drugs, increase in number of product approvals and product launch and surge in adoption of novel hepatitis drugs in the treatment of various types of hepatitis. In addition, surge in research collaborations for the development of robust drugs pipeline drives the growth of the market. Moreover, partnerships and collaboration in major companies, rise in patient awareness regarding hepatitis therapeutics therapy, and introduction of low-priced hepatitis therapeutics are the other factors that boost the growth of the market.

However, high cost of hepatitis drugs is expected to restrain the growth of the hepatitis therapeutics market. Conversely, growth opportunities in emerging markets are expected to offer lucrative opportunities during the forecast period.

The hepatitis therapeutics market is segmented on the basis of disease type, drug class, distribution channel, and region. On the basis of disease type, the market is categorized into Hepatitis B, Hepatitis C, and Others (A, D, E and G). By drug class, the market is divided into oral antivirals, and immune modulators. By distribution channel, the market is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global genome editing market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps understand the applications and applications of mother & child healthcare used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS


By Disease Type

  • Hepatitis B
  • Hepatitis C
  • Others (A, D, E and G)

By Drug Class

  • Oral antivirals
  • Immune modulators

By Distribution Channel

  • Hospital pharmacies
  • Drug stores & retail pharmacies
  • Online providers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle East and Africa

Table of Contents

CHAPTER 1: INTRODUCTION
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increasing Product Approvals and Launches
3.5.1.2. Rising Collaborations between Major Players in the Market
3.5.1.3. Robust Presence of Pipeline Drugs
3.5.2. Restraint
3.5.2.1. High Cost of Hepatitis Drugs
3.5.3. Opportunities
3.5.3.1. Growth Opportunities in Emerging Markets
3.5.4. Impact analysis
3.6. Covid-19 Impact analysis on hepatitis therapeutics market
CHAPTER 4: HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Hepatitis B
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Hepatitis C
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Others (A, D, E and G)
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral Antivirals
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Immune Modulators
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
CHAPTER 6: HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Drug Stores & Retail Pharmacies
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Online Providers
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: HEPATITIS THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. hepatitis therapeutics market, by Disease Type
7.2.2.1.2. U.S. hepatitis therapeutics market, by Drug Class
7.2.2.1.3. U.S. hepatitis therapeutics market, by Distribution Channel
7.2.2.2. Canada
7.2.2.2.1. Canada hepatitis therapeutics market, by Disease Type
7.2.2.2.2. Canada hepatitis therapeutics market, by Drug Class
7.2.2.2.3. Canada hepatitis therapeutics market, by Distribution Channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico hepatitis therapeutics market, by Disease Type
7.2.2.3.2. Mexico hepatitis therapeutics market, by Drug Class
7.2.2.3.3. Mexico hepatitis therapeutics market, by Distribution Channel
7.2.3. North America market size and forecast, by Disease Type
7.2.4. North America market size and forecast, by Drug Class
7.2.5. North America market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country129
7.3.2.1. Germany
7.3.2.1.1. Germany hepatitis therapeutics market, by Disease Type
7.3.2.1.2. Germany hepatitis therapeutics market, by Drug Class
7.3.2.1.3. Germany hepatitis therapeutics market, by Distribution Channel
7.3.2.2. France
7.3.2.2.1. France hepatitis therapeutics market, by Disease Type
7.3.2.2.2. France hepatitis therapeutics market, by Drug Class
7.3.2.2.3. France hepatitis therapeutics market, by Distribution Channel
7.3.2.3. UK
7.3.2.3.1. UK hepatitis therapeutics market, by Disease Type
7.3.2.3.2. UK hepatitis therapeutics market, by Drug Class
7.3.2.3.3. UK hepatitis therapeutics market, by Distribution Channel
7.3.2.4. Italy
7.3.2.4.1. Italy hepatitis therapeutics market, by Disease Type
7.3.2.4.2. Italy hepatitis therapeutics market, by Drug Class
7.3.2.4.3. Italy hepatitis therapeutics market, by Distribution Channel
7.3.2.5. Spain
7.3.2.5.1. Spain hepatitis therapeutics market, by Disease Type
7.3.2.5.2. Spain hepatitis therapeutics market, by Drug Class
7.3.2.5.3. Spain hepatitis therapeutics market, by Distribution Channel
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe hepatitis therapeutics market, by Disease Type
7.3.2.6.2. Rest of Europe hepatitis therapeutics market,
by Drug Class
7.3.2.6.3. Rest of Europe hepatitis therapeutics market,
by Distribution Channel
7.3.3. Europe market size and forecast, by Disease Type
7.3.4. Europe market size and forecast, by Drug Class
7.3.5. Europe market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan hepatitis therapeutics market, by Disease Type
7.4.2.1.2. Japan hepatitis therapeutics market, by Drug Class
7.4.2.1.3. Japan hepatitis therapeutics market, by Distribution Channel
7.4.2.2. China
7.4.2.2.1. China hepatitis therapeutics market, by Disease Type
7.4.2.2.2. China hepatitis therapeutics market, by Drug Class
7.4.2.2.3. China hepatitis therapeutics market, by Distribution Channel
7.4.2.3. Australia161
7.4.2.3.1. Australia hepatitis therapeutics market, by Disease Type
7.4.2.3.2. Australia hepatitis therapeutics market, by Drug Class
7.4.2.3.3. Australia hepatitis therapeutics market, by Distribution Channel
7.4.2.4. India
7.4.2.4.1. India hepatitis therapeutics market, by Disease Type
7.4.2.4.2. India hepatitis therapeutics market, by Drug Class
7.4.2.4.3. India hepatitis therapeutics market, by Distribution Channel
7.4.2.5. South Korea
7.4.2.5.1. South Korea hepatitis therapeutics market, by Disease Type
7.4.2.5.2. South Korea hepatitis therapeutics market, by Drug Class
7.4.2.5.3. South Korea hepatitis therapeutics market, by Distribution Channel
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific hepatitis therapeutics market,
by Disease Type
7.4.2.6.2. Rest of Asia-Pacific hepatitis therapeutics market,
by Drug Class
7.4.2.6.3. Rest of Asia-Pacific hepatitis therapeutics market,
by Distribution Channel
7.4.3. Asia-Pacific market size and forecast, by Disease Type
7.4.4. Asia-Pacific market size and forecast, by Drug Class
7.4.5. Asia-Pacific market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country177
7.5.2.1. Latin America
7.5.2.1.1. Latin America hepatitis therapeutics market, by Disease Type
7.5.2.1.2. Latin America hepatitis therapeutics market, by Drug Class179
7.5.2.1.3. Latin America hepatitis therapeutics market, by Distribution Channel
7.5.2.2. Middle East and Africa
7.5.2.2.1. Middle East and Africa hepatitis therapeutics market, by Disease Type
7.5.2.2.2. Middle East and Africa hepatitis therapeutics market, by Drug Class182
7.5.2.2.3. Middle East and Africa hepatitis therapeutics market, by Distribution Channel
7.5.3. LAMEA market size and forecast, by Disease Type
7.5.4. LAMEA market size and forecast, by Drug Class
7.5.5. LAMEA market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY PROFILES
8.1. ABBVIE INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. BRISTOL MAYERS & SQUIBB
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. CIPLA INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. GILEAD SCIENCES INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. GLAXOSIMITHKLINE PLC
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. HOFFMANN-LA ROCHE LTD.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.7. LUPIN LTD.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Key strategic moves and developments
8.8. MERCK & CO. INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.1. Business performance
8.9.2. Key strategic moves and developments
8.10. ZYUDUS CADILA
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product Portfolio
8.10.4. Business performance
8.10.5. Key strategic moves and developments
List of Tables
TABLE 01. HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 02. HEPATITIS B HEPATITIS THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03. HEPATITIS C HEPATITIS THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04. OTHERS (A, D, E AND G) HEPATITIS THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05. HUMAN HEPATITIS THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06. HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 07. HEPATITIS THERAPEUTICS MARKET FOR CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 08. HEPATITIS THERAPEUTICS MARKET FOR CANCER, BY TYPE, 2020–2030 ($MILLION)
TABLE 09. HEPATITIS THERAPEUTICS MARKET FOR IMMUNE MODULATORS, BY REGION, 2020-2030 ($MILLION)
TABLE 10. HEPATITIS THERAPEUTICS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 11. HEPATITIS THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 12. HEPATITIS THERAPEUTICS MARKET FOR OTHER DRUG CLASSS, BY REGION, 2020-2030 ($MILLION)
TABLE 13. HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 14. HEPATITIS THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 15. HEPATITIS THERAPEUTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020-2030 ($MILLION)
TABLE 16. HEPATITIS THERAPEUTICS MARKET FOR OTHER DISTRIBUTION CHANNEL, BY REGION, 2020-2030 ($MILLION)
TABLE 17. HEPATITIS THERAPEUTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 18. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 19. U.S. HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 20. U.S. HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 21. U.S. HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 22. CANADA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 23. CANADA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 24. CANADA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 25. MEXICO HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 26. MEXICO HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 27. MEXICO HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 28. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 29. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 30. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 31. EUROPE HEPATITIS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 32. GERMANY HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 33. GERMANY HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 34. GERMANY HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 35. FRANCE HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION
TABLE 36. FRANCE HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 37. FRANCE HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 38. UK HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 39. UK HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 40. UK HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 41. ITALY HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 42. ITALY HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 43. ITALY HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 44. SPAIN HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 45. SPAIN HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 46. SPAIN HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 47. REST OF EUROPE HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 48. REST OF EUROPE HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 49. REST OF EUROPE HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 50. EUROPE HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 51. EUROPE HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 52. EUROPE HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 53. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 54. JAPAN HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 55. JAPAN HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 56. JAPAN HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 57. CHINA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 58. CHINA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 59. CHINA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 60. AUSTRALIA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 61. AUSTRALIA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 62. AUSTRALIA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 63. INDIA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 64. INDIA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 65. INDIA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 66. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 67. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 68. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 72. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 73. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 74. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 75. LAMEA HEPATITIS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 76. BRAZIL HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 77. BRAZIL HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 78. BRAZIL HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 79. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 80. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 81. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 82. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 83. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 84. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 85. REST OF LAMEA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 86. REST OF LAMEA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 87. REST OF LAMEA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 88. LAMEA HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 89. LAMEA HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS, 2020–2030 ($MILLION)
TABLE 90. LAMEA HEPATITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 91. ABBVIE: COMPANY SNAPSHOT
TABLE 92. ABBVIE: OPERATING SEGMENTS
TABLE 93. ABBVIE : PRODUCT PORTFOLIO
TABLE 94. BMS: COMPANY SNAPSHOT
TABLE 95. BMS: PRODUCT PORTFOLIO
TABLE 96. CIPLA: COMPANY SNAPSHOT
TABLE 97. CIPLA: OPERATING SEGMENTS
TABLE 98. CIPLA: PRODUCT PORTFOLIO
TABLE 99. GILEAD: COMPANY SNAPSHOT
TABLE 100. GILEAD: OPERATING SEGMENTS
TABLE 101. GILEAD: PRODUCT PORTFOLIO
TABLE 102. GSK: COMPANY SNAPSHOT
TABLE 103. GSK: OPERATING SEGMENTS
TABLE 104. GSK: PRODUCT PORTFOLIO
TABLE 105. ROCHE: COMPANY SNAPSHOT
TABLE 106. ROCHE: OPERATING SEGMENTS
TABLE 107. ROCHE: PRODUCT PORTFOLIO
TABLE 108. LUPIN: COMPANY SNAPSHOT
TABLE 109. LUPIN: OPERATING SEGMENTS
TABLE 110. LUPIN: PRODUCT PORTFOLIO
TABLE 111. MERCK: COMPANY SNAPSHOT
TABLE 112. MERCK: OPERATING SEGMENTS
TABLE 113. MERCK: PRODUCT PORTFOLIO
TABLE 114. TEVA: COMPANY SNAPSHOT
TABLE 115. TEVA: OPERATING SEGMENTS
TABLE 116. TEVA: PRODUCT PORTFOLIO
TABLE 117. ZYDUS: COMPANY SNAPSHOT
TABLE 118. ZYDUS: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. HEPATITIS THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. HIGH THREAT OF SUBSTITUTES
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. HIGH INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF HEPATITIS B HEPATITIS THERAPEUTICS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF HEPATITIS C HEPATITIS THERAPEUTICS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF OTHERS (A, D, E AND G) HEPATITIS THERAPEUTICS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF HUMAN HEPATITIS THERAPEUTICS MARKET, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR CANCER, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 23. COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR IMMUNE MODULATORS,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24. COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR INFLAMMATORY DISEASES,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25. COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 26. COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR OTHER DRUG CLASSS,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 27. COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY,
2020 & 2030 ($MILLION)
FIGURE 28. COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR RESEARCH INSTITUTES,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 29. COMPARATIVE ANALYSIS OF HEPATITIS THERAPEUTICS MARKET FOR OTHER DISTRIBUTION CHANNEL,
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 30. ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 31. ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 32. BMS: NET SALES, 2018–2020 ($MILLION)
FIGURE 33. BMS: REVENUE SHARE, BY REGION 2020 (%)
FIGURE 34. CIPLA: NET SALES, 2018–2020 ($MILLION)
FIGURE 35. CIPLA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36. CIPLA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37. GILEAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 38. GILEAD: REVENUE SHARE, BY SEGMENT 2020 (%)
FIGURE 39. GILEAD: REVENUE SHARE, BY REGION 2020 (%)
FIGURE 40. GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 41. GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42. GSK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 43. ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 44. ROCHE: REVENUE SHARE, BY SEGMENT 2020 (%)
FIGURE 45. ROCHE: REVENUE SHARE, BY REGION 2020 (%)
FIGURE 46. LUPIN : NET SALES, 2018–2020 ($MILLION)
FIGURE 47. MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 48. MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 49. MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 50. TEVA PHARMACEUTICALS: NET SALES, 2018–2020 ($MILLION)
FIGURE 51. TEVA PHARMACEUTICALS: REVENUE SHARE BY SEGMENT 2020 (%)
FIGURE 52. TEVA PHARMACEUTICALS: REVENUE SHARE, BY REGION 2020 (%)
FIGURE 53. ZYDUS: NET SALES, 2018-2020 (%)
FIGURE 54. ZYDUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 55. ZYDUS: REVENUE SHARE BY REGION 2020 (%)

Companies Mentioned

  • Abbvie Inc.
  • Bristol Myers & Squibb
  • Cipla Inc.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Hoffmann-La Roche Ltd.
  • Lupin Ltd.
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages220
PublishedNovember 2021
Forecast Period2020 - 2030
Estimated Market Value ( USD ) in 2020 $ 14480 Million
Forecasted Market Value ( USD ) by 2030 $ 19716 Million
Compound Annual Growth Rate3.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Global Hepatitis Therapeutics Market by Type (Hepatitis A, Hepatitis B, Hepatitis C), Drug Class (Immune Modulator, Oral Antiviral), Distribution Channel - Forecast 2024-2030 - Product Image

Global Hepatitis Therapeutics Market by Type (Hepatitis A, Hepatitis B, Hepatitis C), Drug Class (Immune Modulator, Oral Antiviral), Distribution Channel - Forecast 2024-2030

  • Report
  • 199 Pages
  • Global
From
Hepatitis Therapeutics Global Market Report 2024 - Product Image

Hepatitis Therapeutics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Global Hepatitis Therapeutics Market 2030 by Hepatitis Type, Drug Class, Drug Type, End-user and Distribution Channel and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints - Product Image

Global Hepatitis Therapeutics Market 2030 by Hepatitis Type, Drug Class, Drug Type, End-user and Distribution Channel and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints

  • Report
  • 180 Pages
  • Global
From
Hepatitis Therapeutics - Global Strategic Business Report - Product Image

Hepatitis Therapeutics - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Hepatitis Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Hepatitis Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 90 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.